A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

NCT06186414 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Interventions

DRUG: SIM0237
DRUG: SIM0237 and BCG
DRUG: SIM0237
DRUG: SIM0237 and BCG

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.

Collaborators

[object Object]